Italia markets open in 7 hours 22 minutes

Organogenesis Holdings Inc (2PQ.BE)

Berlin - Berlin Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,5880+0,0150 (+0,58%)
Alla chiusura: 08:10AM CET
Schermo intero
Chiusura precedente2,5730
Aperto2,5880
Denaro2,5700 x N/D
Lettera2,5920 x N/D
Min-Max giorno2,5880 - 2,5880
Intervallo di 52 settimane2,2490 - 8,1000
Volume1.000
Media Volume0
CapitalizzazioneN/D
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

    CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference, which is being held at The Fontainebleau Miami Beach in Mi

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results

    CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared

  • GlobeNewswire

    Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022

    CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2022 financial results will be reported after the market closes on Wednesday, November 9th. Management will host a conference call at 5:00 p.m. Eastern Time on Nove